NUWELLIS INC (NUWE)
US67113Y4052 - Common Stock
NUWE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Health Care Equipment & Supplies industry. While NUWE seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, NUWE is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NUWE has reported negative net income.
NUWE had a negative operating cash flow in the past year.
NUWE had negative earnings in each of the past 5 years.
In the past 5 years NUWE always reported negative operating cash flow.
1.2 Ratios
NUWE has a worse Return On Assets (-231.70%) than 95.31% of its industry peers.
Looking at the Return On Equity, with a value of -704.98%, NUWE is doing worse than 88.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -231.7% | ||
| ROE | -704.98% | ||
| ROIC | N/A |
ROA(3y)-118.33%
ROA(5y)-169.36%
ROE(3y)-299.28%
ROE(5y)-428.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NUWE has a Gross Margin (56.23%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NUWE has grown nicely.
NUWE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y16.14%
2. Health
2.1 Basic Checks
NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NUWE has more shares outstanding
The number of shares outstanding for NUWE has been increased compared to 5 years ago.
There is no outstanding debt for NUWE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NUWE has an Altman-Z score of -45.51. This is a bad value and indicates that NUWE is not financially healthy and even has some risk of bankruptcy.
NUWE has a Altman-Z score of -45.51. This is amonst the worse of the industry: NUWE underperforms 93.75% of its industry peers.
NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.51 |
ROIC/WACCN/A
WACC9.95%
2.3 Liquidity
NUWE has a Current Ratio of 2.59. This indicates that NUWE is financially healthy and has no problem in meeting its short term obligations.
NUWE has a worse Current ratio (2.59) than 60.42% of its industry peers.
NUWE has a Quick Ratio of 1.96. This is a normal value and indicates that NUWE is financially healthy and should not expect problems in meeting its short term obligations.
NUWE has a worse Quick ratio (1.96) than 60.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.96 |
3. Growth
3.1 Past
NUWE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.78%, which is quite impressive.
Looking at the last year, NUWE shows a small growth in Revenue. The Revenue has grown by 3.75% in the last year.
NUWE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.13% yearly.
EPS 1Y (TTM)89.78%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q68.8%
Revenue 1Y (TTM)3.75%
Revenue growth 3Y6.01%
Revenue growth 5Y12.13%
Revenue growth Q2Q9.02%
3.2 Future
Based on estimates for the next years, NUWE will show a very strong growth in Earnings Per Share. The EPS will grow by 37.18% on average per year.
The Revenue is expected to grow by 20.64% on average over the next years. This is a very strong growth
EPS Next Y78.57%
EPS Next 2Y37.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.51%
Revenue Next 2Y20.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NUWE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUWE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NUWE's earnings are expected to grow with 37.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.18%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NUWE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUWELLIS INC
NASDAQ:NUWE (5/3/2024, 9:06:02 PM)
After market: 0.1705 -0.01 (-5.28%)0.18
-0.03 (-12.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.22M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -231.7% | ||
| ROE | -704.98% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.23% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.59 | ||
| Quick Ratio | 1.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)89.78%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y78.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.75%
Revenue growth 3Y6.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y